Cost-Effectiveness and the Avoidance of Discrimination in Healthcare: Can We Have Both?

被引:1
|
作者
Lippert-Rasmussen, Kasper [1 ]
机构
[1] Aarhus Univ, Dept Polit Sci, CEPDISC, DK-8000 Aarhus, Denmark
基金
新加坡国家研究基金会;
关键词
ableism; ageism; compounding injustice; discrimination; distributive justice in healthcare; healthcare rationing; moral worth; QALY; QALYS; EQUITY; PEOPLE; NICE;
D O I
10.1017/S096318012200024X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Many ethical theorists believe that a given distribution of healthcare is morally justified only if (1) it is cost-effective and (2) it does not discriminate against older adults and disabled people. However, if (3) cost-effectiveness involves maximizing the number of quality-adjusted life-years (QALYs) added by a given unit of healthcare resource, or cost, it seems the pursuit of cost-effectiveness will inevitably discriminate against older adults and disabled patients. I show why this trilemma is harder to escape than some theorists think. We cannot avoid it by using age- or disability-weighted QALY scores, for example. I then explain why there is no sense of "discrimination" on which discrimination is both unjust, and thus something healthcare rationing must avoid, and something cost-effective healthcare rationing inevitably involves. I go on to argue that many of the reasons we have for not favoring rationing that maximizes QALYs outside the healthcare context apply in healthcare as well. Thus, claim (1) above is dubious.
引用
收藏
页码:202 / 215
页数:14
相关论文
共 50 条
  • [41] Scientists have questioned the cost-effectiveness of warfarin testing
    不详
    [J]. PHARMACOGENOMICS, 2009, 10 (03) : 331 - 331
  • [42] DOES MEDICARE HAVE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD?
    Chambers, J.
    Neumann, P. J.
    Buxton, M. J.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A15 - A16
  • [43] COST-EFFECTIVENESS OF CHOLESTYRAMINE - WHO SHOULD WE TREAT
    OSTER, G
    EPSTEIN, AM
    [J]. CLINICAL RESEARCH, 1986, 34 (02): : A379 - A379
  • [44] Cost-effectiveness of Obesity Interventions: Will We Know It When We See It?
    Finkelstein, Eric A.
    [J]. PEDIATRICS, 2017, 140 (03)
  • [45] Cost-Effectiveness of Multidisciplinary Pain Treatment: Are We There Yet?
    Clark, Michael E.
    [J]. PAIN MEDICINE, 2009, 10 (05) : 778 - 779
  • [46] HOME HEALTH COST-EFFECTIVENESS - WHAT ARE WE MEASURING
    LAVOR, J
    CALLENDER, M
    [J]. MEDICAL CARE, 1976, 14 (10) : 866 - 872
  • [47] Cost-effectiveness of TAVR in low-risk patients: do we have more than a NOTION?
    Galper, Benjamin Z.
    Baron, Suzanne J.
    Cohen, David J.
    [J]. EUROINTERVENTION, 2019, 15 (11) : E953 - E955
  • [48] The long-term effectiveness and cost-effectiveness of public health interventions; how can we model behavior? A review
    Squires, Hazel
    Kelly, Michael P.
    Gilbert, Nigel
    Sniehotta, Falko
    Purshouse, Robin C.
    [J]. HEALTH ECONOMICS, 2023, 32 (12) : 2836 - 2854
  • [49] Assesing the costs, benefits, cost-benefit ratio, and cost-effectiveness of martial and family treatments: Why we should and how we can
    Fals-Stewart, W
    Yates, BT
    Klosterman, K
    [J]. JOURNAL OF FAMILY PSYCHOLOGY, 2005, 19 (01) : 28 - 39
  • [50] Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
    Arinaminpathy, Nimalan
    Nandi, Arindam
    Vijayan, Shibu
    Jha, Nita
    Nair, Sreenivas A.
    Kumta, Sameer
    Dewan, Puneet
    Rade, Kiran
    Vadera, Bhavin
    Rao, Raghuram
    Sachdeva, Kuldeep S.
    [J]. BMJ GLOBAL HEALTH, 2021, 6 (10):